Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00287846
Recruitment Status : Completed
First Posted : February 7, 2006
Last Update Posted : August 30, 2016
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : February 2006
  Study Completion Date : June 2010
Publications of Results:
Fayette J, Dufresne A, Penel N, et al.: Imatinib for the treatment of aggressive fibromatosis/desmoid tumors (AF/DT) failing local treatment: updated outcome and predictive factors for progression free survival: a FNCLCC French Sarcoma Group-GETO study. [Abstract] J Clin Oncol 25 (Suppl 18): A-10062, 560s, 2007.